Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

International Journal of Cancer

Volumn 98, Issue 2, 2002, Pages 310-315

  Naruse, Ichiro ^a,c   Ohmori, Tohru ^b   Ao, Yoko ^b   Fukumoto, Hisao ^a   Kuroki, Toshio ^b   Mori, Masatomo ^c   Saijo, Nagahiro ^a   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

EGFR; MDR; Resistance; Tyrosine kinase inhibitor; ZD1839

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MESSENGER RNA; PHORBOL ESTER; PHOSPHOTYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; K562 CELLS; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, NEOPLASM; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0037051103     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10173     Document Type: Article

References (43)

1. The molecular genetics of cancer
2. Viral oncogenes
3. A thousand and one protein kinases
4. Signal transduction by receptors with tyrosine kinase activity
5. Receptors for epidermal growth factor and other polypeptide mitogens
6. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
7. Transforming growth factors produced by certain human tumor cells: Polypeptides that interact with epidermal growth factor receptors
8. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
9. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer
10. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: Correlation with clinical outcome and response to chemotherapy
11. Epidermal growth factor receptors in non-small cell lung cancer
12. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
13. Studies leading to the identification of ZD1839 (iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
14. ZD1839 ('Iressa') as an anticancer agent
15. The EGF receptor family as targets for cancer therapy
16. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
17. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
18. Multidrug resistance: Clinical relevance in solid tumors and strategies for circumvention
19. Multidrug resistance and its reversal
20. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
21. Congenital jaundice in rats with mutation in a multidrug resistance-associated protein gene
22. Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-o-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated muti-drug resistance
23. Epidermal growth factor receptor is increased in multidrug-resistant Chines hamster and mouse tumor cells
24. Reversal of mutidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line
25. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones
26. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
27. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line
28. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells
29. Regulation of multidrug resistance through the cAMP and EGF signalling pathways
30. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
31. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
32. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
33. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
34. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-resistance
35. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines
36. Esstablishment of a docetaxel-resistant human non-small cell lung cancer cell line
37. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB
38. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody
39. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f
40. Characterisation of a vindesine-resistant human small-cell lung cancer cell line
41. Characterization of a taxol-resistant human small-cell lung cancer cell line
42. Establishment of a CPT-11-resistant human ovarian cancer cell line
43. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones